Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy

André Altmann, Michal Rosen-Zvi, Mattia Prosperi, Ehud Aharoni, Hani Neuvirth, Eugen Schülter, Joachim Büch, Daniel Struck, Yardena Peres, Francesca Incardona, Anders Sönnerborg, Rolf Kaiser, Maurizio Zazzi, Thomas Lengauer

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Analysis of the viral genome for drug resistance mutations is state-of-the-art for guiding treatment selection for human immunodeficiency virus type 1 (HIV-1)-infected patients. These mutations alter the structure of viral target proteins and reduce or in the worst case completely inhibit the effect of antiretroviral compounds while maintaining the ability for effective replication. Modern anti-HIV-1 regimens comprise multiple drugs in order to prevent or at least delay the development of resistance mutations. However, commonly used HIV-1 genotype interpretation systems provide only classifications for single drugs. The EuResist initiative has collected data from about 18,500 patients to train three classifiers for predicting response to combination antiretroviral therapy, given the viral genotype and further information. In this work we compare different classifier fusion methods for combining the individual classifiers. Principal Findings: The individual classifiers yielded similar performance, and all the combination approaches considered performed equally well. The gain in performance due to combining methods did not reach statistical significance compared to the single best individual classifier on the complete training set. However, on smaller training set sizes (200 to 1,600 instances compared to 2,700) the combination significantly outperformed the individual classifiers (p
    Original languageEnglish
    Article numbere3470
    JournalPLoS ONE
    Volume3
    Issue number10
    Publication statusPublished - 21 Oct 2008

    Fingerprint

    Dive into the research topics of 'Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy'. Together they form a unique fingerprint.

    Cite this